Trial Profile

Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S-49076 (Primary) ; Gefitinib
Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors IRIS; Servier

03 Apr 2019 Results of molecular profiling of T790M-negative NSCLC patients progressing on EGFR-TKI, presented at the 110th Annual Meeting of the American Association for Cancer Research
28 Nov 2018 This trial has been Discontinued in Spain (End date: 2018-11-07).
08 Aug 2018 This trial has been completed in Hungary.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com